Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
SiPore21 improves glycaemic control in prediabetes
Última actualización 12 de septiembre de 2026
Key finding
SiPore21 significantly reduced HbA1c from baseline (p = 0.0036)
The study evaluated SiPore21's effects on glycaemic control and metabolic health in adults with prediabetes or early type 2 diabetes, finding significant improvements in several health markers.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated SiPore21's effects on glycaemic control and metabolic health in adults with prediabetes or early type 2 diabetes, finding significant improvements in several health markers.
Clinical relevance
These findings are clinically significant as they indicate that SiPore21 may not only help manage blood sugar levels but also improve overall metabolic health. This could potentially reduce the risk of progression from prediabetes to type 2 diabetes, a major health concern worldwide. By addressing multiple health markers, SiPore21 could serve as a comprehensive treatment option for individuals at risk.
Keep in mind
Limited generalizability due to specific participant characteristics Short duration of follow-up may not capture long-term effects Potential for unmeasured confounders affecting outcomes
Published in
Referencia de la Revista
Publication details and source links for this paper.
Jeanha B, Anna I, Melissa LB, et al. SiPore21 Improves Glycaemic Control and Metabolic Health in Adults with Prediabetes or Early Type 2 Diabetes. eClinicalMedicine. 2026;97:104042. doi:10.1016/j.eclinm.2026.104042
Efectos Principales
SiPore21 significantly reduced HbA1c by -0.91 mmol/mol (p = 0.0036)
SiPore21 improved body weight by -1.14 kg (p = 0.0374)
SiPore21 was associated with reduced progression from prediabetes to diabetes (p = 0.0233)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to SiPore21 and Body fat mass, Body weight, HbA1c, and 4 more.
This study contributes evidence to
Primary intervention
SiPore21
Primary outcomes
- Body fat mass
- Body weight
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
7
Evidence pairs
7
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
7
Evidence pairs
1123
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 7 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
Weight Loss
matched_outcome
Evidencia relacionada
Tema de evidencia
Body Composition
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerPrediabetes progression to T2D
SiPore21 → Prediabetes progression to T2D
SiPore21 → Prediabetes progression to T2D
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- SiPore21 reduced HbA1c levels significantly (p = 0.0036)
- Body weight decreased by an average of -1.14 kg (p = 0.0374)
- Improved LDL-C levels by -6.17 mg/dL (p = 0.035)
A quién se aplica
- Adults aged 18-65 with prediabetes or early type 2 diabetes
- Individuals seeking to improve metabolic health and glycaemic control
Tener en Cuenta
- Results may not apply to populations outside the study demographics
- Further research is needed to confirm long-term effects
- The study did not assess all potential side effects of SiPore21
Entre Líneas
- Limited generalizability due to specific participant characteristics
- Short duration of follow-up may not capture long-term effects
- Potential for unmeasured confounders affecting outcomes
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SiPore21 and Body Composition, SiPore21 and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Diet and Nutrition
SiPore21 → Body Composition
Diet and Nutrition
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceDiet and Nutrition
SiPore21 → Body Weight
Diet and Nutrition
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceDiet and Nutrition
SiPore21 → Adipokine and Angiogenic Markers
Diet and Nutrition
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Adipokine and Angiogenic Markers Evidence Hub
All studies measuring Adipokine and Angiogenic Markers
1 studies
outcome_hubMeasures Adipokine and Angiogenic Markers as a key outcome.
Body Composition Evidence Hub
All studies measuring Body Composition
1 studies
outcome_hubMeasures Body Composition as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
SiPore21 Evidence Hub
All studies on SiPore21
1 studies
intervention_hubContributes to SiPore21 evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on SiPore21 and Body fat mass
Intervention: SiPore21Outcome: Body fat mass
1 results
All studies on SiPore21 and Body weight
Intervention: SiPore21Outcome: Body weight
1 results
All studies on SiPore21
Intervention: SiPore21
1 results
All studies measuring Body fat mass
Outcome: Body fat mass
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SiPore21 improve body fat mass?
Emerging Evidence
SiPore21 appears to improve body fat mass.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does SiPore21 affect body weight?
Emerging Evidence
SiPore21 appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does SiPore21 lower HbA1c?
Emerging Evidence
SiPore21 appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does SiPore21 improve ldl cholesterol?
Emerging Evidence
SiPore21 appears to improve ldl cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
LDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Video education improves dietary compliance for diabetesCombination Therapy Reduces HbA1c and Weight in Type 2 DiabetesDietary interventions improve glycemic control in pre-diabetic patientsHigh-protein diet may reduce cardiometabolic risks in diabetes patientsInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.